People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotech / Pharma, Biotechnology, Other, Pharmaceuticals, AI / ML
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Greenlight Biosciences Inc. | — | Biotech / Pharma | Series D+ | $179.4M | $3.9B | 2013 |
| SQZ Biotechnologies Co | — | Biotechnology | Series C | $166.6M | $2.7B | 2015 |
| Q-State Holdings, Inc. | — | Biotechnology | Series C | $86.1M | $869.1M | 2018 |
| Molecular Biometrics Inc | — | Biotechnology | Series A | $25.3M | $461.1M | 2009 |
| Railrunner Na Inc | — | Other | Series A | $19.5M | $92.1M | 2010 |
| Continuus Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $7.7M | $154.9M | 2014 |
| Onc.ai, Inc. | — | AI / ML | Series A | $6.0M | $182.5M | 2020 |
| Aquacultural Research Corp | — | Other | Seed | $3.3M | $6.2M | 2015 |
| EnClear Therapies, Inc. | — | Other | Pre-Seed | $718K | $3.4M | 2024 |
Jonathan Fleming at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jonathan Fleming on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter Barrett | 1 | 18 |
| Matthew Walker | 1 | 11 |
| Robert Young | 1 | 9 |
| Michael Liang | 1 | 9 |
| Jason Dinges | 1 | 8 |
| David Furneaux | 1 | 8 |
| Ganesh Kishore | 1 | 7 |
| Eric O'Brien | 1 | 6 |
| Andrey Zarur | 1 | 6 |
| Robert Ackerman | 1 | 6 |
| Jason Camm | 1 | 5 |
| Andrew Ross | 1 | 4 |
| Edward L. Erickson | 1 | 4 |
| Charles Cooney | 1 | 4 |
| Neil Renninger | 1 | 4 |
| Charles L. Cooney | 1 | 4 |
| Jonathan Thomas | 1 | 4 |
| Martha Schlicher | 1 | 4 |
| Garry A. Nicholson | 1 | 3 |
| James Datin | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.